Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 22707550)

1.

Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone.

Gupta S, Bhatt VR, Varma S.

BMJ Case Rep. 2011 Feb 23;2011. pii: bcr1120103516. doi: 10.1136/bcr.11.2010.3516.

2.

Electrolyte disturbances and acute kidney injury induced by imatinib therapy.

de Oliveira RA, Marques ID, Seguro AC, Andrade L.

NDT Plus. 2009 Feb;2(1):27-9. doi: 10.1093/ndtplus/sfn188. Epub 2008 Dec 4.

3.

Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

Ustun C, Randall N, Podgaetz E, Amin K, Dincer HE.

Thorax. 2015 Jul;70(7):701-4. doi: 10.1136/thoraxjnl-2015-206841. Epub 2015 May 2. No abstract available.

PMID:
25935168
4.

Successful maintenance of molecular remission in chronic myelogenous leukaemia during pregnancy with transition from imatinib to pegylated interferon.

Ellis M, Mills AK.

Intern Med J. 2015 Mar;45(3):358-9. doi: 10.1111/imj.12687. No abstract available.

PMID:
25735582
5.

Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review.

Teo YL, Ho HK, Chan A.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):231-42. doi: 10.1517/17425255.2015.983075. Epub 2014 Nov 15.

PMID:
25400226
6.

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.

Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D.

Int J Hematol. 2014 Jan;99(1):91-4. doi: 10.1007/s12185-013-1474-x. Epub 2013 Nov 22.

PMID:
24264834
7.

Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Shah RR, Morganroth J, Shah DR.

Drug Saf. 2013 Jul;36(7):491-503. doi: 10.1007/s40264-013-0048-4. Review.

PMID:
23620168
8.

[Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].

Miyashita K, Fujimaki K, Ishigatsubo Y.

Gan To Kagaku Ryoho. 2013 Mar;40(3):405-7. Japanese.

PMID:
23507609
9.

Imatinib-induced Stevens-Johnsons syndrome.

Jha P, Himanshu D, Jain N, Singh AK.

BMJ Case Rep. 2013 Jan 23;2013. pii: bcr2012007926. doi: 10.1136/bcr-2012-007926.

10.

Successful treatment of nilotinib-induced pleural effusion with prednisone.

Chakraborty K, Bossaer JB, Patel R, Krishnan K.

J Oncol Pharm Pract. 2013 Jun;19(2):175-7. doi: 10.1177/1078155212447530. Epub 2012 Nov 15.

PMID:
23154573
11.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R.

Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Review.

12.

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

Duman BB, Paydas S, Disel U, Besen A, Gurkan E.

Leuk Lymphoma. 2012 Sep;53(9):1706-8. doi: 10.3109/10428194.2012.666545. Epub 2012 Apr 2. Review.

PMID:
22329351
13.

Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.

Papaioannou G, Athanasiadou A, Voutiadou G, Gaitatzi M, Batsis I, Touloumenidou T, Anagnostopoulos A.

Cancer Genet. 2011 Dec;204(12):692-3. doi: 10.1016/j.cancergen.2011.11.004. No abstract available.

PMID:
22285023
14.

[Severe imatinib-induced hepatotoxicity].

García Hernández FJ, González León R, Castillo Palma MJ, Sánchez Román J.

Med Clin (Barc). 2012 May 19;138(14):638; author reply 638-9. doi: 10.1016/j.medcli.2011.09.034. Epub 2011 Dec 3. Spanish. No abstract available.

PMID:
22137996
15.

The safety profile of imatinib in CML and GIST: long-term considerations.

Thanopoulou E, Judson I.

Arch Toxicol. 2012 Jan;86(1):1-12. doi: 10.1007/s00204-011-0729-7. Epub 2011 Jun 30. Review.

PMID:
21717109
16.

[Survival following liver transplant due to imatinib-induced acute liver failure: a case study].

García-Valdés M, Miras López M, Garrido Corro B, De La Rubia Nieto A.

Farm Hosp. 2012 Jan-Feb;36(1):50-1. doi: 10.1016/j.farma.2010.12.004. Epub 2011 Apr 22. Spanish. No abstract available.

PMID:
21514865
17.

Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.

Smith BD.

J Natl Cancer Inst. 2011 Apr 6;103(7):527-9. doi: 10.1093/jnci/djr073. Epub 2011 Mar 21. No abstract available.

18.

Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW.

J Natl Cancer Inst. 2011 Apr 6;103(7):553-61. doi: 10.1093/jnci/djr060. Epub 2011 Mar 21.

19.

Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?

Stagno F, Vigneri P, Di Raimondo F.

Lancet Oncol. 2011 Feb;12(2):118. doi: 10.1016/S1470-2045(11)70017-1. No abstract available.

PMID:
21277547
20.

[Chronic myeloid leukemia. Diagnostics, therapy and future strategy].

Burchert A, Neubauer A.

Internist (Berl). 2011 Mar;52(3):283-93; quiz 294-5. doi: 10.1007/s00108-010-2791-2. Review. German.

PMID:
21253680
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk